Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T Cell Product in Autoimmune Disease

NCT07085104 is registered in ClinicalTrials.gov with Allogene Therapeutics as lead sponsor.

NCT NCT07085104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07085104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T Cell Product in Autoimmune Disease
Lead sponsor
Allogene Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
November 13, 2025
Completion date
October 31, 2032
Enrollment
66 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic inflammatory myopathy, systemic lupus erythematosus (with and without nephritis), systemic sclerosis